{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T10:14:34Z","timestamp":1784196874935,"version":"3.55.0"},"reference-count":49,"publisher":"Georg Thieme Verlag KG","issue":"04","funder":[{"name":"Royal Free Charity","award":["TF 35"],"award-info":[{"award-number":["TF 35"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hamostaseologie."],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>For several decades, the treatment of haemophilia has relied on factor replacement therapy, which restores haemostasis by replacing the missing coagulation factor. In recent years, novel alternative therapies for the treatment of haemophilia in patients with and without inhibitors have been developed. These emergent therapies promote haemostasis by mimicking coagulation factors or inhibiting natural anticoagulants. They provide a less invasive route of administration (i.e. subcutaneous) and some offer reduced frequency of dosing (i.e. every 2 weeks, monthly) compared with the majority of factor replacement therapies, and thus have the potential to simplify treatment, increase adherence and subsequently improve outcomes for patients. Their introduction has transformed the care of haemophilia patients with inhibitors to factor VIII, with similar expectation for haemophilia B patients with inhibitors. However, these therapies also come with several new challenges including their limitation to prophylactic treatment, the observed increased incidence of thrombosis, or their impact on the natural history of the disease and potential disruption of existing treatment guidelines like the use of immune tolerance induction. Moreover, questions remain regarding the long-term impact of non-replacement therapies on joint health as well as the optimal strategy to manage breakthrough bleeds in patients with inhibitors.<\/jats:p>","DOI":"10.1055\/a-1424-7900","type":"journal-article","created":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T22:57:44Z","timestamp":1625007464000},"page":"247-256","source":"Crossref","is-referenced-by-count":12,"title":["Nonfactor Therapies: New Approaches to Prophylactic Treatment of Haemophilia"],"prefix":"10.1055","volume":"41","author":[{"given":"Pratima","family":"Chowdary","sequence":"additional","affiliation":[{"name":"Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free London NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2021,6,29]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd ed","volume":"26","author":"A Srivastava","year":"2020","journal-title":"Haemophilia"},{"issue":"03","key":"ref2","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1055\/s-0037-1615621","article-title":"Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis","volume":"85","author":"G C White II","year":"2001","journal-title":"Thromb Haemost"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0140-6736(15)01123-X","article-title":"The past and future of haemophilia: diagnosis, treatments, and its complications","volume":"388","author":"F Peyvandi","year":"2016","journal-title":"Lancet"},{"issue":"06","key":"ref4","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"M J Manco-Johnson","year":"2007","journal-title":"N Engl J Med"},{"issue":"03","key":"ref5","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2516.2011.02682.x","article-title":"Identification and long-term observation of early joint damage by magnetic resonance imaging in clinically asymptomatic joints in patients with haemophilia A or B despite prophylaxis","volume":"18","author":"M Olivieri","year":"2012","journal-title":"Haemophilia"},{"issue":"06","key":"ref6","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1111\/hae.14098","article-title":"Optimal trough levels in haemophilia B: raising expectations","volume":"26","author":"C Walsh","year":"2020","journal-title":"Haemophilia"},{"issue":"05","key":"ref7","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1055\/s-0040-1709519","article-title":"Modeling to predict factor VIII levels associated with zero bleeds in patients with severe hemophilia a initiated on tertiary prophylaxis","volume":"120","author":"P Chowdary","year":"2020","journal-title":"Thromb Haemost"},{"issue":"13","key":"ref8","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1182\/blood.2020005673","article-title":"Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study","volume":"137","author":"R Klamroth","year":"2021","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.thromres.2019.12.012","article-title":"Extended half-life recombinant products in haemophilia clinical practice - Expectations, opportunities and challenges","volume":"196","author":"P Chowdary","year":"2020","journal-title":"Thromb Res"},{"issue":"07","key":"ref12","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1160\/TH17-01-0030","article-title":"Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX\/IXa and X\/Xa, emicizumab, depends on its ability to bridge the antigens","volume":"117","author":"T Kitazawa","year":"2017","journal-title":"Thromb Haemost"},{"key":"ref13","first-page":"162","article-title":"Pharmacodynamic data and coagulation biomarkers in persons with hemophilia A (PwHA) with inhibitors: results from the HAVEN 1 emicizumab (ACE910) phase 3 study","volume":"1","author":"J I Adamkewicz","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"issue":"09","key":"ref14","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"J Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"issue":"09","key":"ref15","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"J Mahlangu","year":"2018","journal-title":"N Engl J Med"},{"issue":"06","key":"ref16","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3026(19)30054-7","article-title":"Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study","volume":"6","author":"S W Pipe","year":"2019","journal-title":"Lancet Haematol"},{"issue":"24","key":"ref17","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2019001869","article-title":"A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors","volume":"134","author":"G Young","year":"2019","journal-title":"Blood"},{"issue":"06","key":"ref18","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/hae.13848","article-title":"A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors","volume":"25","author":"M Shima","year":"2019","journal-title":"Haemophilia"},{"issue":"09","key":"ref19","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1111\/jth.14491","article-title":"Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: experience from the HAVEN clinical program","volume":"17","author":"G G Levy","year":"2019","journal-title":"J Thromb Haemost"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood-2020-134905","article-title":"Real-world safety of emicizumab: the first interim analysis of the European Haemophilia Safety Surveillance (EUHASS) Database","volume":"136","author":"A Shang","year":"2020","journal-title":"Blood"},{"key":"ref22","first-page":"458","article-title":"Real-world experience with emicizumab in persons with hemophilia A (HA) with or without Inhibitors","volume":"4","author":"M Lewandowska","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"23","key":"ref23","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood-2017-08-801662","article-title":"Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?","volume":"130","author":"P J Lenting","year":"2017","journal-title":"Blood"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1111\/jth.14203","article-title":"In vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents","volume":"16","author":"R Hartmann","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref25","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/hae.13495","article-title":"Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee","volume":"24","author":"P W Collins","year":"2018","journal-title":"Haemophilia"},{"issue":"03","key":"ref26","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/hae.13990","article-title":"Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors","volume":"26","author":"A Bowyer","year":"2020","journal-title":"Haemophilia"},{"issue":"06","key":"ref27","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/hae.14177","article-title":"Effects of emicizumab on APTT, FVIII assays and FVIII Inhibitor assays using different reagents: results of a UK NEQAS proficiency testing exercise","volume":"26","author":"A Lowe","year":"2020","journal-title":"Haemophilia"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1182\/blood-2019-128159","article-title":"Next-generation FVIII mimetic shows superior effect in a FIX- and Fx-humanized mouse model in vivo","volume":"134","author":"C D Ley","year":"2019","journal-title":"Blood"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1182\/blood-2019-122817","article-title":"Mim8\u2013a next-generation FVIII mimetic bi-specific antibody \u2013 potently restores the hemostatic capacity in hemophilia A settings in vitro and in vivo","volume":"134","author":"S L Kjellev","year":"2019","journal-title":"Blood"},{"key":"ref30","first-page":"43","article-title":"Preclinical characterisation of Mim8\u2013a next-generation FVIII mimetic bispecific antibody","volume":"26","author":"S L Kjellev","year":"2020","journal-title":"Haemophilia"},{"key":"ref31","first-page":"40","article-title":"Improved effect of Mim8, a next-generation FVIII mimetic, translates from human in vitro to humanized mouse and cynomolgus models","volume":"26","author":"C D Ley","year":"2020","journal-title":"Haemophilia"},{"issue":"09","key":"ref32","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1616569","article-title":"Targeting of antithrombin in hemophilia A or B with RNAi therapy","volume":"377","author":"K J Pasi","year":"2017","journal-title":"N Engl J Med"},{"key":"ref33","first-page":"86","article-title":"Fitusiran, an RNAi therapeutic targeting antithrombin to restore hemostatic balance in hemophilia: interim analysis from the open-label extension study","volume":"3","author":"K J Pasi","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2147\/JBM.S159297","article-title":"An investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia A and B","volume":"9","author":"N Machin","year":"2018","journal-title":"J Blood Med"},{"key":"ref35","first-page":"314","article-title":"Fitusiran, an RNAi therapeutic targeting antithrombin to restore hemostatic balance in hemophilia: management of acute bleeding events","volume":"3","author":"S W Pipe","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"issue":"01","key":"ref37","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s12185-018-2548-6","article-title":"Anti-tissue factor pathway inhibitor (TFPI) therapy: a novel approach to the treatment of haemophilia","volume":"111","author":"P Chowdary","year":"2020","journal-title":"Int J Hematol"},{"issue":"24","key":"ref38","doi-asserted-by":"crossref","first-page":"5871","DOI":"10.1182\/blood-2012-01-401620","article-title":"Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model","volume":"119","author":"I Hilden","year":"2012","journal-title":"Blood"},{"issue":"05","key":"ref39","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/jth.12864","article-title":"Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial","volume":"13","author":"P Chowdary","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"11","key":"ref40","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1111\/jth.14272","article-title":"A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A","volume":"16","author":"H Eichler","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"22","key":"ref41","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1182\/blood.2019001542","article-title":"Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A\/B with inhibitors: phase 2 trial results","volume":"134","author":"A D Shapiro","year":"2019","journal-title":"Blood"},{"issue":"04","key":"ref43","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1208\/s12248-017-0086-4","article-title":"Mechanistic modeling of the pharmacodynamic and pharmacokinetic relationship of tissue factor pathway inhibitor-neutralizing antibody (BAY 1093884) in cynomolgus monkeys","volume":"19","author":"J M Gu","year":"2017","journal-title":"AAPS J"},{"key":"ref44","first-page":"77","article-title":"Anti-TFPI antibody BAY-1093884: early termination of phase II dose-escalation study due to thrombosis","volume":"26","author":"F Ferrante","year":"2020","journal-title":"Haemophilia"},{"issue":"09","key":"ref45","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1111\/jth.14207","article-title":"A first-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06741086, an anti-tissue factor pathway inhibitor mAb, in healthy volunteers","volume":"16","author":"M Cardinal","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref46","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/MOH.0000000000000364","article-title":"Targeting activated protein C to treat hemophilia","volume":"24","author":"S GI Polderdijk","year":"2017","journal-title":"Curr Opin Hematol"},{"issue":"01","key":"ref47","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1182\/blood-2016-05-718635","article-title":"Design and characterization of an APC-specific serpin for the treatment of hemophilia","volume":"129","author":"S G Polderdijk","year":"2017","journal-title":"Blood"},{"issue":"01","key":"ref48","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1182\/blood-2016-11-748822","article-title":"Correcting the hemophilic imbalance","volume":"129","author":"D A Lane","year":"2017","journal-title":"Blood"},{"issue":"05","key":"ref49","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1111\/hae.12759","article-title":"Health-related quality of life assessment in haemophilia patients on prophylaxis therapy: a systematic review of results from prospective clinical trials","volume":"21","author":"A O Oladapo","year":"2015","journal-title":"Haemophilia"},{"issue":"07","key":"ref50","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/jth.12990","article-title":"Inhibitor development and mortality in non-severe hemophilia A","volume":"13","author":"C L Eckhardt","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"10","key":"ref51","doi-asserted-by":"crossref","first-page":"e28474","DOI":"10.1002\/pbc.28474","article-title":"Outcomes in children with hemophilia A with inhibitors: results from a noninterventional study","volume":"67","author":"J Oldenburg","year":"2020","journal-title":"Pediatr Blood Cancer"},{"issue":"05","key":"ref52","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1111\/hae.13822","article-title":"Safety and efficacy of emicizumab and other novel agents in newborns and infants","volume":"25","author":"G F Pierce","year":"2019","journal-title":"Haemophilia"},{"issue":"04","key":"ref53","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/hae.13762","article-title":"The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab","volume":"25","author":"M Carcao","year":"2019","journal-title":"Haemophilia"},{"issue":"01","key":"ref54","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3324\/haematol.2019.239160","article-title":"Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study","volume":"106","author":"C Male","year":"2021","journal-title":"Haematologica"}],"container-title":["H\u00e4mostaseologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1424-7900.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T22:31:31Z","timestamp":1628893891000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1424-7900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,29]]},"references-count":49,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2021,8,13]]},"published-print":{"date-parts":[[2021,8]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1424-7900","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0720-9355","2567-5761"],"issn-type":[{"value":"0720-9355","type":"print"},{"value":"2567-5761","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,29]]}}}